- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04828460
Monitoring of COVID-19 Vaccine Response in Organ Transplant Patients (COVATRANS)
Vaccination against SARS CoV-2 appears to be the best strategy today to control the COVID-19 pandemic. The first published studies with Pfizer, Moderna and Astra-Zeneca vaccines show very good vaccine protection in the general population and good short-term tolerance. The efficacy of these vaccines ranges from 62 to 95%, which is particularly remarkable, especially for mRNA vaccines. Nevertheless, these studies do not report the vaccine response in organ transplant patients.
It is known that transplant patients have lower vaccine responses than immunocompetent patients due to some degree of immunosuppression.
Therefore, the investigators are interested in evaluating the vaccine response of organ transplant recipients after vaccination against SARS- CoV-2. For non-responder patients, new strategies can be proposed: 3rd or 4th boost of vaccine or perfusion/injection of antiS monoclonal antibodies. These strategies must be evaluated.
Studieoversikt
Status
Forhold
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Strasbourg, Frankrike, 67000
- Rekruttering
- Hopitaux Universitaires de Strasbourg
-
Ta kontakt med:
- Sophie Ohlmann, MD
- Telefonnummer: 33 0369551320
- E-post: sophie.ohlmann@chru-strasbourg.fr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
- Eldre voksen
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Patient, male or female, adult or child (15 years and older)
- Patient vaccinated against SARS-CoV-2 as part of routine care, and having received the 2 injections
- Solid organ transplant recipient
- Transplantation for more than 3 months
Exclusion Criteria:
- History of anaphylactic shock or known allergy to PEG
- Known history of COVID or positive Covid serology in the 3 months preceding inclusion
- Formal contraindication to an intra-muscular injection
- Impossibility to give the subject informed information (subject in emergency situation, difficulties in understanding the subject, ...)
- Subject under legal protection
- Subject under guardianship or curatorship
- Patient having expressed his opposition to participate
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Kidney transplant recipients who receive Covid-19 vaccine
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Percentage of patients who develop a seroconversion for SARS Cov-2 anti Spike antibodies
Tidsramme: One month after the 2nd injection of the COVID-19 vaccine
|
One month after the 2nd injection of the COVID-19 vaccine
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Compare the seroconversion between different vaccines
Tidsramme: At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine
|
At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine
|
Percentage of patients who develop a seroconversion for SARS Cov-2 anti Spike antibodies
Tidsramme: At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine and at Month 1 after the 3rd and 4th injection.
|
At Month 3, Month 6, Month12 and Month 24 after the 2nd injection of the COVID-19 vaccine and at Month 1 after the 3rd and 4th injection.
|
Describe the patients characteristics associated with seroconversion
Tidsramme: At Month 24 after the 2nd injection of the COVID-19 vaccine
|
At Month 24 after the 2nd injection of the COVID-19 vaccine
|
Assess the tolerance of the 3rd and 4th doses of vaccine in transplant patients
Tidsramme: At the day of injection, Month 1, Month 2, Month 3, Month 6 and Month 12 post injection
|
At the day of injection, Month 1, Month 2, Month 3, Month 6 and Month 12 post injection
|
Percentage of patients who develop a Seroconversion for SARS Cov-2 anti Spike and anti N antibodies after injection of monoclonal antibodies
Tidsramme: At Month 1, Week 6, Week 8, Month 3, Month 6 and Month 12 afin injection of monoclonal antibodies
|
At Month 1, Week 6, Week 8, Month 3, Month 6 and Month 12 afin injection of monoclonal antibodies
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 8133
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Covid-19
-
HealthQuiltFullførtImmunfunksjon | Covid19 positiv pasient | Covid19 nærkontaktForente stater
-
VA Office of Research and DevelopmentAktiv, ikke rekrutterendeKOLS-pasienter og pasienter som kommer seg etter COVID19Forente stater
-
Bahçeşehir UniversityFullførtLang Covid19 | Autonom dysfunksjonTyrkia
-
Ohio State UniversityRekrutteringPost-akutt COVID19-syndrom | Lang COVID | Tilstand etter COVID19Forente stater
-
Brugmann University HospitalRekruttering
-
North Carolina Central UniversityLumbee Tribe of North Carolina; University of North Carolina at PembrokeRekrutteringCovid19 virusinfeksjonForente stater
-
Istituti Clinici Scientifici Maugeri SpAIstituto Auxologico Italiano; Azienda Ospedaliera Bolognini di Seriate... og andre samarbeidspartnereFullført
-
Bassett HealthcareBioreference, IncFullført
-
Gamaleya Research Institute of Epidemiology and...Government of the city of Moscow; CRO: Crocus Medical BVUkjentCovid19-forebyggingDen russiske føderasjonen
-
Texas Woman's UniversityNational Institutes of Health (NIH)Har ikke rekruttert ennå